| Reporting Segment and Geographic Information |
10. Reporting Segment and Geographic Information The Company views its operations and manages its business in one reporting segment. Long-lived assets are primarily located in the United States as of March 31, 2025 and December 31, 2024. Revenue by region for the three-months ended March 31, 2025 and 2024 were as follows (in thousands):
|
|
|
|
|
|
|
|
Three-Months Ended |
|
|
March 31, 2025 |
|
March 31, 2024 |
|
Revenue by region: |
|
|
|
|
United States |
$ |
17,756 |
|
$ |
10,532 |
|
Japan |
|
634 |
|
|
461 |
|
European Union |
|
49 |
|
|
51 |
|
Australia |
|
40 |
|
|
17 |
|
United Kingdom |
|
35 |
|
|
43 |
|
Total |
$ |
18,514 |
|
$ |
11,104 |
|
Revenue by customer type for the three-months ended March 31, 2025 and 2024 were as follows (in thousands):
|
|
|
|
|
|
|
|
Three-Months Ended |
|
|
March 31, 2025 |
|
March 31, 2024 |
|
Revenue by customer type: |
|
|
|
|
Commercial sales |
$ |
18,450 |
|
$ |
11,068 |
|
Deferred commercial revenue recognized |
|
8 |
|
|
8 |
|
BARDA revenue for right of first access |
|
56 |
|
|
28 |
|
Total |
$ |
18,514 |
|
$ |
11,104 |
|
Commercial revenue by product for the three-months ended March 31, 2025 and 2024 were as follows (in thousands):
|
|
|
|
|
|
|
|
Three-Months Ended |
|
|
March 31, 2025 |
|
March 31, 2024 |
|
Commercial revenue by product: |
|
|
|
|
RECELL |
$ |
17,675 |
|
$ |
10,962 |
|
Other wound care products |
|
586 |
|
|
106 |
|
Lease revenue |
|
189 |
|
|
- |
|
Total commercial sales |
$ |
18,450 |
|
$ |
11,068 |
|
Consolidated net loss by segment for the three-months ended March 31, 2025 and 2024 were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, 2025 |
|
March 31, 2024 |
|
Total revenues |
|
$ |
18,514 |
|
$ |
11,104 |
|
Purchases of inventory |
|
|
(2,497 |
) |
|
(1,237 |
) |
Other cost of sales |
|
|
(336 |
) |
|
(276 |
) |
Gross profit |
|
|
15,681 |
|
|
9,591 |
|
Operating expenses: |
|
|
|
|
|
Sales and marketing |
|
|
(14,834 |
) |
|
(12,640 |
) |
General and administrative |
|
|
(6,390 |
) |
|
(8,963 |
) |
Research and development |
|
|
(6,284 |
) |
|
(5,194 |
) |
Total operating expenses |
|
|
(27,508 |
) |
|
(26,797 |
) |
Operating loss |
|
|
(11,827 |
) |
|
(17,206 |
) |
Interest expense |
|
|
(1,233 |
) |
|
(1,356 |
) |
Other expense, net |
|
|
(791 |
) |
|
(66 |
) |
Loss before income taxes |
|
|
(13,851 |
) |
|
(18,628 |
) |
Income tax expense |
|
|
(8 |
) |
|
(30 |
) |
Net loss |
|
$ |
(13,859 |
) |
$ |
(18,658 |
) |
|